Welcome to our dedicated page for Calidi Biotherapeutics news (Ticker: CLDI), a resource for investors and traders seeking the latest updates and insights on Calidi Biotherapeutics stock.
Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage immuno-oncology company at the forefront of advancing cancer treatment methodologies. The company specializes in the development and commercialization of innovative, stem cell-based platforms designed to enhance the delivery and effectiveness of oncolytic viruses in cancer therapy.
Calidi’s core business involves leveraging its proprietary Neuro-Cells™ and SuperNova™ technology platforms. These platforms are engineered to deliver oncolytic viruses directly to tumor sites, ensuring targeted and potent cancer cell destruction while minimizing damage to surrounding healthy tissues.
Among the company's recent achievements, Calidi has successfully completed several preclinical studies demonstrating the efficacy and safety of its therapeutic candidates. Currently, Calidi is undergoing multiple Phase I/II clinical trials to further validate these findings and advance towards regulatory approvals.
Financially, Calidi Biotherapeutics has secured significant investment and formed strategic partnerships with key players in the biotechnology and pharmaceutical industries. These collaborations aim to accelerate the development timelines and expand the potential applications of their oncolytic virus therapies.
Calidi’s commitment to innovation and excellence is evident in its robust pipeline of products and ongoing research initiatives. The company continues to explore new avenues for the application of its technologies, with the ultimate goal of offering effective and life-saving treatments for cancer patients worldwide.
For the latest updates and news about Calidi Biotherapeutics, including their ongoing clinical trials and partnerships, visit their official news section.
Calidi Biotherapeutics (NYSE American: CLDI) has been granted U.S. Patent No. 12,036,278 for its SuperNova technology platform. This patent, titled 'Smallpox Vaccine for Cancer Treatment,' covers methods and compositions related to cancer immunotherapy, specifically combining smallpox vaccines with various stem cell types.
The patent strengthens Calidi's intellectual property portfolio and supports the advancement of its CLD-201 program into clinical trials. It broadens previously allowed claims to include 21 smallpox vaccine virus strains and 19 different stem cell types. The SuperNova platform aims to shield viral payloads from the immune system, enhancing delivery to tumor sites and improving the therapeutic efficacy of oncolytic viruses.
Calidi plans to submit an IND to initiate a first-in-human clinical trial of this off-the-shelf allogeneic therapy, focusing on patients with advanced solid tumors.
Calidi Biotherapeutics (NYSE American: CLDI) has appointed Dr. Mark Gilbert, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board. Dr. Gilbert, former Chief of the Neuro-Oncology Branch at NIH, brings extensive experience in brain tumor research and clinical trials. His addition expands the board to eight members, joining other renowned oncologists and scientists.
Dr. Gilbert expressed interest in Calidi's SNV1 and NNV1 therapies, noting their potential to address rare cancers affecting about 25% of cancer patients. Calidi's CEO, Allan Camaisa, highlighted Dr. Gilbert's expertise in developing multi-institutional studies and partnerships with national centers of excellence, which could advance Calidi's research efforts.
Calidi Biotherapeutics (NYSE American: CLDI) will implement a 1-for-10 reverse stock split, effective July 15, 2024. The stock will trade on a split-adjusted basis under the same ticker, CLDI. This decision, approved by shareholders on June 6, 2024, aims to reduce outstanding shares to one-tenth of the pre-split amount.
No fractional shares will be issued; fractional entitlements will be rounded up. The split will adjust equity awards, warrants, and exercise prices accordingly. Shareholders with book-entry or brokerage accounts need not take action, while those with certificate shares will receive instructions from Computershare.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech firm focused on antitumor virotherapies, has appointed Dr. George E. Peoples to its Board of Directors, effective July 1, 2024. Dr. Peoples is renowned in cancer immunotherapy, with over 20 years of experience in developing and testing cancer vaccines. He is the Founder and Director of the Cancer Vaccine Development Program and has held significant roles in both military and clinical settings. His expertise is expected to aid Calidi in advancing their cancer immunotherapies into later-stage clinical trials. CEO Allan Camaisa highlighted Dr. Peoples’ pioneering work and extensive experience as key assets for the company’s growth.
Calidi Biotherapeutics, a clinical-stage biotechnology firm, is hosting a live investor webinar on June 13, 2024, at 4:15 p.m. ET. The event, organized by RedChip Companies, will feature insights from the Chief Business Officer, Stephen Thesing, and CFO, Andrew Jackson. Calidi focuses on developing next-generation immunotherapies, specializing in oncolytic virotherapy (OV) to target and eliminate cancer cells. Their proprietary cell-based technologies protect OVs from immune system elimination and modify the tumor microenvironment for enhanced therapeutic outcomes. The webinar will also include a live Q&A session. Register here: Webinar Registration.
Calidi Biotherapeutics has partnered with SIGA Technologies to advance its RTNova virotherapy for lung cancer and metastatic solid tumors. RTNova leverages a vaccinia virus enveloped by a human cell membrane to evade immunity and enhance therapeutic functions. SIGA will supply TPOXX, an antiviral agent against vaccinia virus, to support RTNova's development. This collaboration aims to create a universal treatment for all tumor types and will initially focus on lung cancer and metastatic solid tumors. RTNova's novel approach allows for easy administration and a broader patient reach. The partnership offers a safety mechanism for clinical trials, ensuring better regulatory compliance and patient safety.
Calidi Biotherapeutics presented significant updates at the 2024 ASCO Annual Meeting, focusing on their NeuroNova (CLD-101), RTNova (CLD-400), and SuperNova (CLD-201) programs. CLD-101's Phase 1 trial is progressing, with safety and feasibility confirmed for up to four weekly doses in patients with high-grade gliomas. Preclinical data on RTNova showed its ability to target and reach tumors systemically, while SuperNova (CLD-201) demonstrated promising non-clinical results, with no adverse toxicity and effective tumor volume reduction. These findings underscore Calidi's innovative approach to antitumor virotherapy and reinforce their commitment to advancing targeted immunotherapies.
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a definitive agreement for the immediate exercise of certain outstanding Series B and C warrants. This move allows the purchase of up to 10,698,000 shares of Calidi’s common stock at a reduced price of $0.20 per share, generating gross proceeds of approximately $2.1 million.
The funds will be used to support Calidi’s clinical and pre-clinical programs and cover operating expenses. In exchange, Calidi will issue new unregistered warrants with an exercise price of $0.30 per share, exercisable upon shareholder approval, and expiring five and a half years from the issuance date.
This offering is expected to close by June 3, 2024, and is facilitated by Ladenburg Thalmann & Co as the exclusive placement agent. The new warrants will be offered in a private placement under Section 4(a)(2) of the Securities Act of 1933.
ASP Isotopes (Nasdaq:ASPI) and Calidi Biotherapeutics (NYSE American:CLDI) will be featured on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing May 25 at 7 p.m. ET. ASP Isotopes CEO Paul Mann will discuss the company's advancements in nuclear medicine and green nuclear energy, emphasizing its strong financial position with no long-term debt and significant cash reserves. H.C. Wainwright reaffirmed its buy rating, raising the price target to $5.50. Calidi Biotherapeutics CEO Allan Camaisa will highlight their cutting-edge oncolytic virotherapy (OV) treatments for cancer, showcasing promising initial study results and innovative IV-based technology for enhanced treatment efficacy.
Calidi Biotherapeutics (NYSE American: CLDI) and Unusual Machines (NYSE American: UMAC) will feature on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing on May 18 at 7 p.m. ET.
Calidi Biotherapeutics, led by CEO Allan Camaisa, specializes in oncolytic virotherapy (OV) for cancer treatment. Their engineered viruses target cancer cells and bolster the immune system, showing promising initial study results. Calidi's unique technologies enhance OV efficacy and treatment potential.
Unusual Machines, headed by CEO Allan Evans, focuses on the drone industry. The company is growing through strategic acquisitions and development of FPV products, aiming to serve various industries like consumer, public safety, and drone delivery. Subsidiaries Fat Shark and Rotor Riot lead in FPV experiences, positioning the company for long-term success.
FAQ
What is the current stock price of Calidi Biotherapeutics (CLDI)?
What is the market cap of Calidi Biotherapeutics (CLDI)?
What is Calidi Biotherapeutics, Inc.?
What technologies does Calidi Biotherapeutics use?
What is the current focus of Calidi Biotherapeutics?
Has Calidi Biotherapeutics achieved any recent milestones?
Who are Calidi Biotherapeutics' industry partners?
What is the goal of Calidi’s stem cell-based platforms?
What are oncolytic viruses?
Where can I find the latest news about Calidi Biotherapeutics?
What are the main products of Calidi Biotherapeutics?
What is the long-term vision of Calidi Biotherapeutics?
